Aged hepatocytes that become senescent detect rising intracellular hydrophobic bile acids and, instead of merely dying, secrete a tailored SASP that enhances FXR activity in nearby parenchymal cells. This paracrine FXR activation suppresses de novo bile acid synthesis and upregulates efflux transporters, thereby limiting bile acid toxicity. Senolytic removal of these cells would blunt this adaptive FXR boost, leading to transient bile acid accumulation and exacerbated liver injury unless compensated by pharmacologic FXR agonism.

Mechanistic rationale

1. Bile acid‑triggered senescence – Hydrophobic bile acids (e.g., deoxycholic acid) induce DNA damage and p21‑dependent senescence in hepatocytes (see 1).
2. SASP composition – Senescent hepatocytes enrich their secretome with extracellular vesicles (EVs) containing miR‑192‑5p and IGFBP3, both shown to potentiate FXR transcriptional activity in recipient cells (2).
3. FXR‑mediated homeostatic program – FXR activation induces SHP, which represses CYP7A1 (rate‑limiting bile acid synthesis) and upregulates BSEP and MDR3 transporters, reducing intracellular bile acid load (4).
4. Adaptive sacrifice – By adopting a senescent state, hepatocytes halt proliferation but preserve tissue‑wide bile acid homeostasis through this paracrine FXR‑boosting signal.

Testable predictions

• Prediction 1: In aged mouse livers, isolating CD44‑positive senescent hepatocytes will yield EVs enriched for miR‑192‑5p and IGFBP3 compared with EVs from young hepatocytes.
• Prediction 2: Treating primary hepatocytes from young mice with EVs from aged senescent hepatocytes will increase FXR target gene expression (Shp, Bsep, MDR3) and decrease CYP7A1 mRNA; this effect will be blocked by GW9662 (FXR antagonist) or anti‑miR‑192 oligonucleotides.
• Prediction 3: Chronic administration of a senolytic (e.g., dasatinib + quercetin) to 20‑month‑old mice will reduce hepatic senescent cell burden (p16^Ink4a^ immunostaining) but concomitantly lower hepatic FXR activity (reduced Shp, Bsep) and raise serum total bile acids, accompanied by increased ALT/AST and hepatic fibrosis markers unless co‑treated with an FXR agonist (e.g., obeticholic acid).
• Prediction 4: Rescue of the senolytic‑induced bile acid dysregulation by FXR agonism will normalize bile acid pools, reduce hepatocyte apoptosis, and improve liver histology without altering senescent cell numbers.

Experimental approach

• Use p16‑3MR mice to track and selectively eliminate senescent hepatocytes via ganciclovir or pharmacologic senolytics.
• Isolate hepatocyte‑derived EVs by ultracentrifugation; quantify miR‑192‑5p and IGFBP3 by qPCR/Western blot.
• Measure FXR signaling (luciferase reporter, target gene expression), bile acid synthesis (CYP7A1 activity), and efflux (BSEP/MDR3) in vitro and in vivo.
• Perform metabolomic profiling of serum and hepatic bile acids (LC‑MS) to detect shifts in primary/secondary ratios.
• Histological assessment (H&E, Sirius Red, TUNEL) to correlate senolytic treatment, FXR activity, and liver injury.

Falsifiability

If senescent hepatocyte‑derived EVs do not enhance FXR signaling, or senolytic clearance fails to alter FXR target genes or bile acid levels despite robust senocyte depletion, the hypothesis is refuted. Conversely, confirmation of the predicted EV‑mediated FXR boost and the detrimental metabolic consequences of senocyte loss would support the notion that senescent hepatocytes serve as adaptive “hostage negotiators” in the bile acid‑FXR axis during aging.